Exosomal miRNAs-a diagnostic biomarker acting as a guiding light in the diagnosis of prostate cancer

Funct Integr Genomics. 2022 Dec 27;23(1):23. doi: 10.1007/s10142-022-00951-8.

Abstract

Prostate cancer, one of the major causes of mortality globally is regarded as the second leading cause of mortality among men. It is known to affect the stromal cells surrounding it. Through the use of exosomes, the affected stromal cells can promote the growth and spread of the cancer. Exosomes are known to play a role not only in the development and progression of cancer but also contribute to the drug-resistance character of cancer cells. Recently, the discovery of the small non-coding RNAs or miRNA has attracted attention of cancer researchers as they can regulate the expression of different genes. Therefore, exosomal miRNA can be used as a novel and reliable biomarker for the diagnosis and treatment of prostate cancer. In addition, exosomal miRNAs can also be used as a potential treatment for prostate cancer. The goal of this review is to provide a comprehensive analysis of the current knowledge about the role of exosomal miRNAs in the treatment of patients with prostate cancer and their potential role in monitoring the disease.

Keywords: Biomarker; Diagnosis; Exosome; Prostate cancer; miRNA.

Publication types

  • Review

MeSH terms

  • Biomarkers / metabolism
  • Exosomes* / genetics
  • Exosomes* / metabolism
  • Humans
  • Male
  • MicroRNAs* / metabolism
  • Prostatic Neoplasms* / diagnosis
  • Prostatic Neoplasms* / genetics
  • Prostatic Neoplasms* / metabolism

Substances

  • MicroRNAs
  • Biomarkers